近年來(lái)乳腺癌、卵巢癌、胰腺癌等實(shí)體瘤的發(fā)病率逐年增加,臨床上還缺乏有效的治療藥物。作為第1個(gè)用于人類(lèi)癌癥療法的聚腺苷二磷酸核糖聚合酶(PARP)抑制劑,臨床前研究表明rucaparib可明顯抑制乳腺癌、卵巢癌等實(shí)體瘤。臨床研究顯示rucaparib具有良好的安全性和有效性。主要從rucaparib的藥物概況、相關(guān)背景、合成路線、臨床前研究和臨床研究方面進(jìn)行介紹。

Recently, the morbidity of breast cancer, ovarian cancer, pancreatic cancer, and other solid tumors has increased year by year, and there is still lack of effective drugs in clinic. As the first poly ADP-ribose polymerase inhibitor for human cancer therapy, preclinical studies show that rucaparib can significantly inhibit breast cancer, ovarian cancer, and other solid tumors. Clinical studies show that rucaparib has good safety and effectiveness. The drug situation, background, route of synthesis, preclinical, and clinical trials researches of rucaparib are reviewed in this paper.